MedTrace Logo

UW-CTRI Triple Medication Smoking Cessation Study

NCT02681510 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2017-10-11

Study results available
· View outcomes & findings →

Summary

This study will focus on enhancing future smoking cessation treatment effectiveness by piloting a potentially more powerful combination of three FDA-approved pharmacotherapies: varenicline plus combination of two types of nicotine replacement therapy (NRT) treatment (nicotine lozenge and nicotine patch). Data from this pilot study will help inform the design of future studies that would use this combination treatment as a cessation tool within the chronic care arsenal of treatments.

Conditions

  • Smoking

Interventions

DRUG

Varenicline

Standard FDA approved 12 weeks of treatment with Varenicline

DRUG

Nicotine Transdermal Patch

Standard FDA approved 12 weeks of treatment with Nicotine Transdermal Patch

DRUG

Nicotine Mini

Standard FDA approved 12 weeks of treatment with Nicotine Mini-Lozenge

Sponsors & Collaborators

  • University of Wisconsin, Madison

    lead OTHER

Principal Investigators

  • Michael C Fiore · University of Wisconsin--CTRI

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2016-06-13
Completion
2016-06-13

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02681510 on ClinicalTrials.gov